Hydroxychloroquine and COVID-19 - A narrative review.
Identifieur interne : 000685 ( Main/Corpus ); précédent : 000684; suivant : 000686Hydroxychloroquine and COVID-19 - A narrative review.
Auteurs : Jyoti Bajpai ; Akshyaya Pradhan ; Abhishek Singh ; Surya KantSource :
- The Indian journal of tuberculosis [ 0019-5707 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Enzyme Inhibitors, Hydroxychloroquine.
- drug therapy : COVID-19.
- chemical , therapeutic use : Enzyme Inhibitors, Hydroxychloroquine.
- Humans, SARS-CoV-2.
Abstract
COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection.
DOI: 10.1016/j.ijtb.2020.06.004
PubMed: 33308661
PubMed Central: PMC7836863
Links to Exploration step
pubmed:33308661Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and COVID-19 - A narrative review.</title><author><name sortKey="Bajpai, Jyoti" sort="Bajpai, Jyoti" uniqKey="Bajpai J" first="Jyoti" last="Bajpai">Jyoti Bajpai</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Pradhan, Akshyaya" sort="Pradhan, Akshyaya" uniqKey="Pradhan A" first="Akshyaya" last="Pradhan">Akshyaya Pradhan</name><affiliation><nlm:affiliation>Department of Cardiology, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Abhishek" sort="Singh, Abhishek" uniqKey="Singh A" first="Abhishek" last="Singh">Abhishek Singh</name><affiliation><nlm:affiliation>Department of Medicine, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Kant, Surya" sort="Kant, Surya" uniqKey="Kant S" first="Surya" last="Kant">Surya Kant</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India. Electronic address: skantpulmed@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33308661</idno><idno type="pmid">33308661</idno><idno type="doi">10.1016/j.ijtb.2020.06.004</idno><idno type="pmc">PMC7836863</idno><idno type="wicri:Area/Main/Corpus">000685</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000685</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine and COVID-19 - A narrative review.</title><author><name sortKey="Bajpai, Jyoti" sort="Bajpai, Jyoti" uniqKey="Bajpai J" first="Jyoti" last="Bajpai">Jyoti Bajpai</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Pradhan, Akshyaya" sort="Pradhan, Akshyaya" uniqKey="Pradhan A" first="Akshyaya" last="Pradhan">Akshyaya Pradhan</name><affiliation><nlm:affiliation>Department of Cardiology, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Abhishek" sort="Singh, Abhishek" uniqKey="Singh A" first="Abhishek" last="Singh">Abhishek Singh</name><affiliation><nlm:affiliation>Department of Medicine, King George's Medical University, Lucknow, 226003, India.</nlm:affiliation></affiliation></author><author><name sortKey="Kant, Surya" sort="Kant, Surya" uniqKey="Kant S" first="Surya" last="Kant">Surya Kant</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India. Electronic address: skantpulmed@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Indian journal of tuberculosis</title><idno type="ISSN">0019-5707</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (drug therapy)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hydroxychloroquine (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33308661</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0019-5707</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4S</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Indian journal of tuberculosis</Title><ISOAbbreviation>Indian J Tuberc</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine and COVID-19 - A narrative review.</ArticleTitle><Pagination><MedlinePgn>S147-S154</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0019-5707(20)30070-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijtb.2020.06.004</ELocationID><Abstract><AbstractText>COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajpai</LastName><ForeName>Jyoti</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Akshyaya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, King George's Medical University, Lucknow, 226003, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, King George's Medical University, Lucknow, 226003, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kant</LastName><ForeName>Surya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India. Electronic address: skantpulmed@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Tuberc</MedlineTA><NlmUniqueID>0373027</NlmUniqueID><ISSNLinking>0019-5707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Immunomodulator</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">QT prolongation</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors have none to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33308661</ArticleId><ArticleId IdType="pii">S0019-5707(20)30070-6</ArticleId><ArticleId IdType="doi">10.1016/j.ijtb.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7836863</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation><ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87</Citation><ArticleIdList><ArticleId IdType="pubmed">23716032</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1988 Jan 7;318(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3336379</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2017 Oct;24:189-194</Citation><ArticleIdList><ArticleId IdType="pubmed">29033372</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation><ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation><ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dermatol. 1980 May;116(5):587-91</Citation><ArticleIdList><ArticleId IdType="pubmed">6990871</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Crit Care Med. 2020 Jan;24(Suppl 1):S6-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">32205954</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation><ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2013 Feb;23(2):300-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23208422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Rheumatol. 2013 Aug;19(5):286-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23872551</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation><ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation><ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105945</Citation><ArticleIdList><ArticleId IdType="pubmed">32194152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jun;80(6):607-613</Citation><ArticleIdList><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 May 1;180(5):698-706</Citation><ArticleIdList><ArticleId IdType="pubmed">32119028</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 May 2;368(18):1665-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23635046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000685 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000685 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33308661
|texte= Hydroxychloroquine and COVID-19 - A narrative review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33308661" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |